Rasio rega marang prakiraan pendapatan Virax Biolabs Corp (VRAX)

Logo perusahaan publik Virax Biolabs Corp (VRAX)

The hiring of virologists and IT specialists to combat infections drove growth, and the projected price-to-sales ratio on GURU.Markets reflects a peak where the metric reached 80.50. Currently, Virax Biolabs Group (VRAX) is implementing ViraxClear systems to expand into the B2B segment, although falling demand for rapid tests and the slow rollout of new products are weighing on capital.

Virax Biolabs Group Limited - Multiplikator Forward P/S VRAX (periode 28.04.2023 - 15.11.2026)

Rincian metrik komprehensif lan analitis Virax Biolabs Group (VRAX)

- rega saiki lan proyeksi nilai saham:
Ringkesan analitik perusahaan:Virax Biolabs Corp VRAX
Produk sing diprodhuksi Virax Biolabs Corp

Forward P/S relates current market capitalization to projected revenue, determining the premium the market is willing to pay for future income growth. For Virax Biolabs Group (VRAX), this metric reflects expectations for the commercialization of ViraxClear systems, where excessive growth on the forward P/S chart may signal an overvaluation of expansion potential within the B2B diagnostics segment.

Analisis perusahaan pesaing

Multiplikator Forward P/S A (agilent.com)|Quest Corp (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ILMN - Rasio rega marang prakiraan pendapatan|EXAS - Multiplikator Forward P/S|RVTY (Revvity) - Multiplikator forward rega marang pendapatan|Bio-Rad - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan anbio.com|Multiplikator Forward P/S Sotera Health Company|Rasio rega marang prakiraan pendapatan QuidelOrtho (QDEL)|OPK - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|caredx.com - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Maravai LifeSciences Corp (MRVI)|FLGT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Rasio rega marang prakiraan pendapatan|OSUR: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan XGN|MDXH: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Lucid Diagnostics Inc. (LUCD)|Rasio rega marang prakiraan pendapatan PRE (Prenetics Global Limited)|Multiplikator Forward P/S IMDX (Insight Molecular Diagnostics Inc)|Rasio rega marang pendapatan sing dikarepake TRIB (Trinity Biotech Corp)|PRPH - Rasio rega marang prakiraan pendapatan|Ainos (AIMD) - Multiplikator forward rega marang pendapatan|CoDx (CODX) - Rasio rega marang prakiraan pendapatan|HSCS (Heart Test Labs) - Rasio rega marang prakiraan pendapatan|BMRA (Biomerica, Inc.) - Multiplikator Forward P/S|CDIO (Cardio Diagnostics) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Onconetix Corp (ONCO)|Rasio rega marang pendapatan sing dikarepake BJDX|Rasio rega marang prakiraan pendapatan Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|centogene.com - Multiplikator Forward P/S|ENZ (Enzo Biochem Inc.) - Kapitalisasi marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep FRES|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GTG Labs (GENE)|ME (23andme.com) - Multiplikator Forward P/S|Multiplikator Forward P/S Psychemedics Inc